Want to join the conversation?
$CELG's selling, general and administrative expenses for 2015 increased by 13.7% from 2014. The rise was primarily due to rises in expenses from supporting inflammation and immunology products and product candidates, such as Otezla as well as rises in selling and marketing activities for Revlimid, Otezla and Pomalyst/Imnovid.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?